Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Herpes zoster in patients with glioma treated with temozolomide.
Hiong A, Lapidus AH, Gately L, Sinclair G, Ameratunga M. Hiong A, et al. Among authors: ameratunga m. J Clin Neurosci. 2024 Nov;129:110816. doi: 10.1016/j.jocn.2024.110816. Epub 2024 Sep 1. J Clin Neurosci. 2024. PMID: 39222582
Symptomatic brain metastases in melanoma.
Knox A, Wang T, Shackleton M, Ameratunga M. Knox A, et al. Among authors: ameratunga m. Exp Dermatol. 2024 Apr;33(4):e15075. doi: 10.1111/exd.15075. Exp Dermatol. 2024. PMID: 38610093 Review.
UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma.
Kuser-Abali G, Zhang Y, Szeto P, Zhao P, Masoumi-Moghaddam S, Fedele CG, Leece I, Huang C, Cheung JG, Ameratunga M, Noguchi F, Andrews MC, Wong NC, Schittenhelm RB, Shackleton M. Kuser-Abali G, et al. Among authors: ameratunga m. Oncogene. 2023 Apr;42(17):1360-1373. doi: 10.1038/s41388-023-02631-8. Epub 2023 Mar 11. Oncogene. 2023. PMID: 36906655 Free PMC article.
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.
Papadatos-Pastos D, Yuan W, Pal A, Crespo M, Ferreira A, Gurel B, Prout T, Ameratunga M, Chénard-Poirier M, Curcean A, Bertan C, Baker C, Miranda S, Masrour N, Chen W, Pereira R, Figueiredo I, Morilla R, Jenkins B, Zachariou A, Riisnaes R, Parmar M, Turner A, Carreira S, Yap C, Brown R, Tunariu N, Banerji U, Lopez J, de Bono J, Minchom A. Papadatos-Pastos D, et al. Among authors: ameratunga m. J Immunother Cancer. 2022 Jun;10(6):e004495. doi: 10.1136/jitc-2022-004495. J Immunother Cancer. 2022. PMID: 35717027 Free PMC article. Clinical Trial.
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Gan HK, Parakh S, Lee FT, Tebbutt NC, Ameratunga M, Lee ST, O'Keefe GJ, Gong SJ, Vanrenen C, Caine J, Giovannetti M, Murone C, Scott FE, Guo N, Burvenich IJG, Paine C, Macri MJ, Kotsuma M, Senaldi G, Venhaus R, Scott AM. Gan HK, et al. Among authors: ameratunga m. Invest New Drugs. 2022 Aug;40(4):747-755. doi: 10.1007/s10637-022-01237-3. Epub 2022 Apr 11. Invest New Drugs. 2022. PMID: 35404015 Clinical Trial.
33 results